Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar-Apr;33(2):413-417.
doi: 10.21873/invivo.11488.

The Evaluation of Proteoglycan Levels and the Possible Role of ACAN Gene (c.6423T>C) Variant in Patients with Lumbar Disc Degeneration Disease

Cumhur Kaan Yaltirik  1 , Özlem Timirci-Kahraman  2 , Seda Gulec-Yilmaz  3 , Selcuk Ozdogan  4 , Basar Atalay  5 , Turgay Isbir  6
Affiliations

The Evaluation of Proteoglycan Levels and the Possible Role of ACAN Gene (c.6423T>C) Variant in Patients with Lumbar Disc Degeneration Disease

Cumhur Kaan Yaltirik et al. In Vivo. 2019 Mar-Apr.

Abstract

Background/aim: The present study aimed to investigate the role of an aggrecan (ACAN) gene variant and proteoglycan levels in the risk of lumbar degenerative disc disease (LDDD).

Materials and methods: A total of 108 patients with LDDD and 103 healthy controls were enrolled. Molecular assessment of the ACAN gene (c.6423T>C) variant was determined by real time-polymerase chain reaction. Proteoglycan levels in serum were measured with enzyme-linked immunosorbent assay.

Results: The frequency of all alleles and genotypes in all study groups were distributed according to the Hardy-Weinberg equilibrium. In addition, no association between the ACAN gene (c.6423T>C) variant and presence of risk factors for LDDD was detected. However, proteoglycan levels were significantly lower in patients with LDDD compared to the control group (p<0.00001).

Conclusion: Our findings suggest that proteoglycan has emerged as a potential novel biomarker which might be used for prediction of LDDD risk.

Keywords: Lumbar disc degenaration; biomarker; single-nucleotide polymorphism.

PubMed Disclaimer

Conflict of interest statement

On behalf of all Authors, the corresponding Author states that there is no conflict of interest in regard to this study.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andersson GB. Epidemiological features of chronic low-back pain. Lancet. 1999;354(9178):581–585. - PubMed
    1. Cervin Serrano S, Gonzalez Villareal D, Aguilar-Medina M, Romero-Navarro JG, Romero Quintana JG, Arambula Meraz E, Osuna Ramirez I, Picos-Cardenas V, Granados J, Estrada-Garcia I, Sanchez-Schmitz G, Ramos-Payan R. Genetic polymorphisms of interleukin-1 alpha and the vitamin D receptor in Mexican Mestizo patients with intervertebral disc degeneration. Int J Genomics. 2014;2014:302568. - PMC - PubMed
    1. Yuceli S. Facet cysts. J Turk Spinal Surg. 2018;29(4):219–221.
    1. Antar V, Baran O, Yüceli S, Erdogan H, Altintas O, Baran GE, Tasdemiroglu E. Assessment of the neuroprotective effects of the acetylcholinesterase inhibitor huperzine A in an experimental spinal cord trauma model. J Neurosurg Sci. 2018;62(2):128–139. - PubMed
    1. Cherkin DC, Deyo RA, Loeser JD, Bush T, Waddell G. An international comparison of back surgery rates. Spine. 1994;19(11):1201–1206. - PubMed

MeSH terms

Supplementary concepts